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Abstract: Transcutaneous electrical nerve stimulation (TENS) refers to the delivery of electrical currents through the skin to 
activate peripheral nerves. The technique is widely used in developed countries to relieve a wide range of acute and chronic 
pain conditions, including pain resulting from cancer and its treatment. There are many systematic reviews on TENS although 
evidence is often inconclusive because of shortcomings in randomised control trials methodology. In this overview the basic 
science behind TENS will be discussed, the evidence of its effectiveness in specific clinical conditions analysed and a case for 
its use in pain management in developing countries will be made. 
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Introduction 
Transcutaneous electrical nerve stimulation (TENS) is 
widely used in western and developed countries to relieve 
a wide range of painful conditions, including non-
malignant acute and chronic pain and pain resulting from 
cancer and its treatment [1-3]. TENS is inexpensive, non-
invasive and safe with no major side effects. TENS can be 
self administered by patients following simple training and 
because there is no potential for toxicity, patients can 
titrate the dosage on an as-needed basis.  During TENS 
pulsed electrical currents are generated by a small battery 
operated TENS device that can be kept in the pocket or 
attached to the user’s belt. Currents from the TENS device 
are delivered through the skin by two self-adhering 
electrode pads (Figure 1).  
 
The purpose of TENS is to selectively activate nerve 
fibers. Maximal pain relief is achieved when TENS 
generates a strong non-painful electrical sensation 
beneath the electrodes. Pain relief is usually rapid in onset 
and stops shortly after TENS is turned off. For this reason 
patients are encouraged to deliver TENS for as long as 
needed, which may be for hours at a time and throughout 
the day. The main contraindication is patients with 
implanted stimulators such as pacemakers. In the UK, 
TENS devices can be purchased without prescription, 
although this is not the case in some European countries. 
TENS devices, including electrode leads, pads and battery, 
retail for approximately £30GBP  although bulk buying can 
markedly reduce cost. Interestingly, TENS does not appear 
to be widely available for patient use in developing 
countries.  
 
In this review the basic science behind TENS will be 
discussed, the evidence of its effectiveness in specific 
clinical conditions will be provided and a case for its use in 
pain management in developing countries will be made. 
 
Physiological principle of TENS induced pain relief  
The ancient Egyptians are usually acknowledged as the 
first people who used electrogenic fish to apply electricity 
for pain relief. Yet, the first documented use of this kind of 
pain relief is of a Roman Physician  in 46 AD [4].  In 1786, 
Luigi Galvani, an Italian doctor, demonstrated that the leg 
of a frog contained electricity. This observation and other 
advancements in generating electricity lead to a 
resurgence in the use of electricity to treat different 
illnesses and relieve pain.  However, increased use of 
pharmacological agents to manage pain resulted in the 
decline of the electrotherapy at the end of the 19th 
century.  In 1965, Ronald Melzack from McGill University 
in Montreal Canada and Patrick Wall from University 
College London UK, published their seminal paper which 
proposed a gating mechanism in the central nervous 
system to regulate the flow of nerve signals from 
peripheral nerves en-route to the brain [5].  According to 
this Gate-Control Theory of Pain, activity in large diameter 
low threshold mechanoreceptive (touch-related) nerve 
fibers could inhibit the transmission of action potentials 
from small diameter higher threshold nociceptive (pain-
related) fibers through pre and post synaptic inhibition in 
the dorsal horn of spinal cord. Humans utilise this 
mechanism whenever they rub their skin to relieve pain. 
Because nociceptive fibers (A-delta and C-fibers) have a 
higher threshold of activation than mechanoreceptive 
fibers (A-beta fibers) Melzack and Wall proposed that it 
would be possible to selectively stimulate 
mechanoreceptive fibers by titrating the amplitude of 
electrical currents delivered across the surface of the skin 
(ie TENS). This would prevent signals from nociceptive 
fibers from reaching higher centres of the brain, thus 
reducing pain (Figures 2). In essence, TENS electrically 
rubs pain away. 
 
In addition to interrupting nociceptive signals, at spinal 
cord dorsal horn, we now know that TENS analgesia also 
involves a descending inhibitory mechanism that could be 
partially prevented by spinalization [6]. Activity in nerve 
fibers descending from the brain can also block onward 
transmission of peripheral nerve signals within the spinal 
cord. Humans utilise this mechanism whenever they 
mentally distract themselves to not feel pain despite the 
presence of tissue damage (Figure 2)  
 
Evidence gathered from animal studies suggested that 
low frequency TENS effects may be due to release of 
endogenous opioids [6]. This explains why analgesia may 
persist for hours after electrical stimulation has stopped 
because endorphins have long lasting effects in the central 
nervous system. The released opioids may generate their 
analgesic action at peripheral, spinal and supraspinal sites 
[7,8]. However, other neurochemicals have been 
implicated in TENS analgesia including GABA [9], 
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acetylcholine [10], 5-HT [11], noradrenaline [12] and 
adenosine [13]. 
 
 
Figure 1 A standard TENS device. 
 
TENS and TENS-like devices 
In health care the term TENS refers to the delivery of 
currents using a ‘standard TENS device’ (Table 1) [3]. 
However, there are a variety of devices that deliver 
electrical currents through the skin but have technical 
output characteristics that differ from a standard TENS 
device. We have previously described these as “TENS-like 
devices” and include Trancutaneous Spinal 
Electroanalgesia, Interferential Therapy, Microcurrent 
Stimulation and Pain Gone pens (see [3,14,15] for a 
review of these devices). The remainder of this review will 
focus on standard TENS devices.  
 
Table 1 Technical output specifications of a standard TENS 
device  
Weight  
Dimensions 
50-250g  
6 x 5 x 2 cm (small device)  
12 x 9 x 4 cm (large device) 
Cost  Approximately £30 
Pulse waveform 
(usually fixed) 
Monophasic symmetrical biphasic 
asymmetrical biphasic  
Pulse amplitude 
(usually adjustable) 
1-50mA into a 1 kΩ load 
Pulse duration 
(sometimes fixed, 
sometimes adjustable) 
10-1000µs  
Pulse frequency 
(usually  adjustable) 
1-250pps  
Pulse pattern  
usually continuous and burst 
available (some devices have 
modulated amplitude, modulated 
frequency, modulated pulse 
duration, random frequency) 
Channels  1 or 2  
Batteries  PP3 (9V), rechargeable 
Additional features 
Timer, most devices deliver 
constant current output 
 
TENS Techniques 
TENS is a technique to stimulate different categories of 
nerve fibers. The most commonly used TENS technique is 
termed conventional TENS. During conventional TENS, 
low-intensity pulsed currents are administered at high-
frequencies (between 10-200 pulses per second, pps) at 
the site of pain. The user experiences a “strong, non-
painful TENS sensation often described as ‘’tingling’ or 
pleasant ‘electrical paraesthesiae’. Physiologically, 
conventional TENS activates large diameter non-noxious 
afferents which has been shown to close the pain gate at 
spinal segments related to the pain [6]. Another 
technique, which is used less often is acupuncture-like 
TENS (AL-TENS) using high-intensity and low-frequency 
(less than 10pps, usually 2pps) administered over 
muscles, acupuncture and trigger points [16]. The purpose 
of AL-TENS is to activate small diameter afferents which 
has been shown to close the pain gate using extra-
segmental mechanisms [2]. TENS can also be used as a 
counter-irritant, termed intense TENS, using high-intensity 
and high-frequency currents (Table 2, Figure 3). 
 
 
Figure 2 Diagrammatic representation of the principle of 
conventional TENS. By selectively activating A-beta fibers, TENS 
shuts the Pain Gate on A-delta and C fibers preventing pain-
related signals reaching the brain. 
 
Clinical effectiveness of TENS 
In Western clinical practice TENS has been shown to 
have a role in pain management [2].  There are many 
systematic reviews on TENS although evidence is often 
inconclusive because of shortcomings in RCT 
methodology. Early systematic reviews suggested that 
TENS was of limited benefit as a stand alone pain therapy 
for acute pain. Carroll et al. judged there to be no benefit 
of TENS for postoperative pain because 15 of 17 RCTs 
found no differences in pain relief between active and 
placebo TENS [17]. However, Bjordal et al. re-assessed 
the evidence and concluded that TENS reduced post-
operative analgesic consumption if TENS was applied 
using adequate TENS technique [18]. Systematic reviews 
have also concluded that there was no evidence for TENS 
producing beneficial analgesic effects during childbirth 
[19,20] and insufficient evidence to determine the 
effectiveness of TENS in reducing pain associated with 
primary dysmenorrhoea [21]. RCTs suggest that TENS is 
effective for acute orofacial pain, painful dental 
procedures, fractured ribs and acute lower back pain (for 
review see [22]. 
 
Previously, systematic reviews suggested that TENS 
may be of benefit for chronic pain but definitive 
conclusions were hindered by shortcomings in RCT 
methodology [23,24]. Reviews on rheumatoid arthritis of 
the hand [25], whiplash and mechanical neck disorders 
[26], chronic low back pain [27], poststroke shoulder pain 
[28] and chronic recurrent headache [29] were 
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Table 2 TENS techniques  
 
 
TENS parameters  
Patient 
experience  
Electrode 
location  
Physiological 
Intention  
Regimen  
Analgesic 
profile 
Conventional 
TENS 
Low intensity 
(amplitude), high 
frequency (10-200 pps) 
 
Strong, non-
painful TENS 
paraesthesia with 
minimal muscle 
activity 
Dermatomes 
Site of pain 
 
To stimulate 
large diameter 
non-noxious 
afferents (A-
beta) to produce 
segmental 
analgesia 
Use TENS 
whenever 
in pain  
Usually 
rapid 
onset and 
offset  
AL-TENS 
High intensity 
(amplitude), low 
frequency (1-5 bursts of 
100 pps) 
 
Strong 
comfortable 
muscle twitching  
Myotomes 
Site of pain 
Muscles 
Motor nerves 
Acupuncture 
points 
To stimulate 
small diameter 
cutaneous and 
motor afferents 
(A-delta) to 
produce 
extrasegmental 
analgesia 
Use TENS 
for 20-30 
minutes at 
a time  
May be 
delayed 
onset and 
offset  
Intense 
TENS 
High amplitude 
(uncomfortable/noxious
), high frequency (50-
200pps)  
Uncomfortable 
(painful) 
electrical 
paraesthesia 
Dermatomes 
Site of pain 
Nerves 
proximal to 
pain 
To stimulate 
small diameter 
cutaneous 
afferents (A-
delta) to produce 
counter irritation  
Short 
periods 
only 5-15 
minutes at 
a time  
Rapid 
onset and 
delayed 
offset  
 
 
inconclusive. In contrast, systematic reviews have 
demonstrated TENS efficacy for knee osteoarthritis [30] 
and chronic musculoskeletal pain [31]. RCTs  have also 
demonstrated effects for a range of other chronic pain 
conditions including localized muscle pain, post-herpetic 
neuralgia, trigeminal neuralgia, phantom limb and stump 
pain and diabetic neuropathies (for review see [3]. A 
recent Cochrane review by Robb et al.  concluded that 
there is insufficient available evidence to determine the 
effectiveness of TENS in treating cancer-related pain 
[32,33]. 
 
Pain Management in developing countries: Could 
TENS help? 
The International Association for The Study of Pain 
(IASP) speculate that “the prevalence of most types of 
pain may be much higher in developing countries than in 
developed countries”, although epidemiological evidence is 
lacking [34]. It is known that there is a higher incidence of 
pain conditions associated with epidemics such as 
HIV/aids in the developing world.  An IASP Developing 
Countries Task Force, which included Africa and the 
Middle East reported that pain management in the general 
population was inadequate, although there was 
considerable variations between regions [35]. Limited 
resources, ignorance by health care professionals and a 
lack of pain specialists were contributing factors. This has 
impacted significantly on pharmacological therapy with 
many drugs commonly used in the developed world being 
unavailable to the general public because of the weak 
economy and limited purchasing power of citizens [36]. In 
addition, drugs even when available may be fake, 
adulterated, passed their expiry date or perished due to 
inadequate storage. 
 
TENS is advantageous in this regard. It is inexpensive 
when compared to drug therapy. The cost of a TENS 
device is £30GBP, although devices are available for less 
than £15GBP if bought in bulk. Once purchased a TENS 
device will not perish or deteriorate and devices in the 
developed world are used for many decades without the 
need for further servicing or repair. Often clinics purchase 
TENS devices in bulk and loan them to patients for short 
and long term use, on the proviso that the patient returns 
the device to the clinic when it is no longer needed. 
Running costs are minimal and include battery and 
reusable electrode pad replacement. Manufacturers 
recommend that individual pads have longevity of one 
month on daily use, although patients often use them for 
far greater lengths of time, especially if they take care to 
store them carefully. Electrode costs can be reduced by 
using carbon rubber electrodes which are smeared with 
electrode gel and attached to the skin with micropore 
tape, rather than using self adhering electrodes. In 
general, battery and electrode use depends on how often 
the patient uses TENS  
 
TENS has no known drug interactions and so can be 
used in combination with pharmacotherapy to reduce 
medication, medication-related side effects and medication 
costs. TENS has very few side effects with no incidents of 
serious or adverse events reported in the literature. TENS 
has a rapid onset of action, unlike medication, and there is 
no potential for toxicity or overdose.  
 
Clearly, there is a case to use TENS for pain 
management in the developing world. However, research 
is needed to determine the feasibility of TENS use in 
developing countries. Perhaps health promotion 
authorities should alert the public and heath care 
practitioners to the role of TENS as an important aid in the 
fight against pain.   
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Figure 3 Output characteristics (settings) of a standard 
TENS device. The user can control the amplitude 
(intensity), duration (width), frequency (rate) and pattern 
(mode) of the pulsed electrical currents. 
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